



Published study confirming effectiveness of transurethral intraprostatic anaesthesia (TUIA) using our Schelin Catheter®

A novel study conducted by an Italian research team has been published in the scientific journal *Prostate Cancer and Prostatic Diseases* (1). The study demonstrates the effectiveness of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® (registered trademark of ProstaLund AB) in patients with benign prostatic enlargement before temporary implantable nitinol device (iTIND, registered trademark of Olympus) procedures.

The study aimed to assess pain scores during and after implantation of the temporary implantable nitinol device. Patients were divided into two groups: one receiving TUIA with the Schelin Catheter®, and the other treated with standard anaesthesia protocols (local anaesthetics in the urethra or conscious intravenous sedation).

The results revealed that pain scores during the procedure and at the time of the nitinol device removal were similar across both groups. However, at 24 and 48 hours post-procedure, the group treated with TUIA using the Schelin Catheter® reported significantly lower pain scores. This is a clinically significant finding, as patients undergoing the temporary implantable nitinol device procedure often experience varying degrees of discomfort during the postoperative period while the device remains in place.

The authors conclude that TUIA with the Schelin Catheter® provides effective and sustained pain relief during and after the procedure, supporting its use in outpatient settings.

Reference:

1. Secco S et al. Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure. *Prostate Cancer Prostatic Dis* (2024). <https://doi.org/10.1038/s41391-024-00892-2>

For further information, please contact:

Anders Kristensson, CEO
Phone: +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com

About Schelin Catheter®

The Schelin Catheter® is a transurethral catheter with a retractable needle enabling sterile intraprostatic injections of pharmaceuticals during diagnostic or treatment procedures for the prostate. The Schelin Catheter® is primarily used for transurethral intraprostatic anaesthesia (TUIA) during minimal invasive treatments for benign prostatic enlargement offering effective pain control, replacing the need for general or spinal anaesthesia. For more information visit, www.schelincatheter.com.



PRESS RELEASE
12 September 2024 15:20:00 CEST

About ProstaLund

ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPE). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 4,000 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser

Västra Hamnen Corporate Finance AB

Phone: +46 (0) 40 200 250

Email: ca@vhcorp.se

Attachments

Published study confirming effectiveness of transurethral intraprostatic anaesthesia (TUIA) using our Schelin Catheter®